234 related articles for article (PubMed ID: 36485090)
1. Ph+ ALL in 2022: is there an optimal approach?
Wieduwilt MJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):206-212. PubMed ID: 36485090
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review.
Jabbour E; Haddad FG; Short NJ; Kantarjian H
JAMA Oncol; 2022 Sep; 8(9):1340-1348. PubMed ID: 35834222
[TBL] [Abstract][Full Text] [Related]
3. Molecular remission after combination therapy with blinatumomab and ponatinib with relapsed/refractory Philadelphia chromosome-positive acute lymphocytic leukemia: two case reports.
Yuda J; Yamauchi N; Kuzume A; Guo YM; Sato N; Minami Y
J Med Case Rep; 2021 Mar; 15(1):164. PubMed ID: 33762010
[TBL] [Abstract][Full Text] [Related]
4. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Zhang Y; Feng S
Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Abou Dalle I; Jabbour E; Short NJ; Ravandi F
Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
[TBL] [Abstract][Full Text] [Related]
6. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
[TBL] [Abstract][Full Text] [Related]
7. [Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era].
Dobashi N
Rinsho Ketsueki; 2020; 61(9):1227-1235. PubMed ID: 33162520
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.
Samra B; Kantarjian HM; Sasaki K; Alotaibi AS; Konopleva M; O'Brien S; Ferrajoli A; Garris R; Nunez CA; Kadia TM; Short NJ; Jabbour E
Acta Haematol; 2021; 144(3):285-292. PubMed ID: 33238261
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
Kidoguchi K; Ureshino H; Kizuka-Sano H; Yamaguchi K; Katsuya H; Kubota Y; Ando T; Miura M; Takahashi N; Kimura S
Int J Hematol; 2021 Aug; 114(2):199-204. PubMed ID: 33907977
[TBL] [Abstract][Full Text] [Related]
10. Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation.
Chen H; Xu LP; Zhang XH; Wang Y; Chen YH; Yan CH; Cheng YF; Han W; Chen Y; Qin YZ; Liu Y; Chang YJ; Liu KY; Huang XJ
Leuk Res; 2022 Oct; 121():106930. PubMed ID: 36007342
[TBL] [Abstract][Full Text] [Related]
11. [Treatment strategy for Philadelphia chromosome-positive acute lymphoblastic leukemia in children].
Shimada H
Rinsho Ketsueki; 2022; 63(7):799-804. PubMed ID: 35922951
[TBL] [Abstract][Full Text] [Related]
12. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
13. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.
Kim K; Jabbour E; Short NJ; Kebriaei P; Kantarjian H; Ravandi F
Curr Oncol Rep; 2021 Jun; 23(8):95. PubMed ID: 34125415
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.
Shahzad M; Hussain A; Tariq E; Anwar I; Faisal MS; Syed L; Karam A; Chaudhary SG; Ahmed N; Bansal R; Khurana S; Singh AK; Byrd KP; Hematti P; Abhyankar SH; McGuirk JP; Mushtaq MU
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):178-187. PubMed ID: 36682989
[TBL] [Abstract][Full Text] [Related]
16. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.
Xiong ZY; Shen YJ; Zhang SZ; Zhu HH
Hematology; 2024 Dec; 29(1):2335856. PubMed ID: 38581291
[TBL] [Abstract][Full Text] [Related]
17. Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia?
Haddad FG; Short NJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):213-217. PubMed ID: 36485089
[TBL] [Abstract][Full Text] [Related]
18. Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era.
Badar T; Alkhateeb H; Aljurf M; Kharfan-Dabaja MA
Curr Res Transl Med; 2023; 71(2):103392. PubMed ID: 37121211
[TBL] [Abstract][Full Text] [Related]
19. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation.
Tachibana T; Najima Y; Akahoshi Y; Hirabayashi S; Harada K; Doki N; Uchida N; Fukuda T; Sawa M; Ogata M; Takada S; Tanaka M; Matsuhashi Y; Tanaka J; Onizuka M; Ichinohe T; Atsuta Y; Kako S;
Ann Hematol; 2020 Oct; 99(10):2393-2404. PubMed ID: 32803312
[TBL] [Abstract][Full Text] [Related]
20. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Wieduwilt MJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]